TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9708556

Group type: EXPERIMENTAL
Intervention: Ultrastructural assessment of dermal connective tissue components via transmission electron microscopy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of cervical artery dissections with connective tissue abnormalities
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Assessment of structural abnormalities in the extracellular matrix
Number of subjects: 25
Study: 8574437

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, two inhalations) administered 30 minutes before exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 30
Study: 1978025

Group type: EXPERIMENTAL
Intervention: Cold provocation in Raynaud's subjects
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cold provocation in control subjects
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Digital arterial pulsatility in Raynaud's subjects
Number of subjects: 14

Group type: COMPARATOR
Intervention: Digital arterial pulsatility in control subjects
Number of subjects: 14
Study: 155097

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 119

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 119
Study: 30616380

Group type: EXPERIMENTAL
Intervention: Cisplatin plus PUFAs (3600 mg/day for three courses, each course included 3 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cisplatin plus placebo
Number of subjects: 34
Study: 28219692

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg oral once daily for 45 days
Number of subjects: 472

Group type: COMPARATOR
Intervention: Fondaparinux 2.5 mg subcutaneous once daily for 45 days
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 472

Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 472
Study: 25222349

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 1700000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1700000
Study: 23604707

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control intervention (3 cycles of 5 min upper-arm cuff inflation to 20 mmHg)
Number of subjects: 30
Study: 22136960

Group type: EXPERIMENTAL
Intervention: n3-LCPUFA (900 mg daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 19210165

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isogenic pfcrt-modified parasite lines
Number of subjects: 0
Study: 16626413

Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of IBS-QOL
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of WPAI:IBS
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Electronic Data Capture (EDC) version of EQ-5D
Number of subjects: 72

Group type: COMPARATOR
Intervention: Paper questionnaire for IBS-QOL
Number of subjects: 72

Group type: COMPARATOR
Intervention: Paper questionnaire for WPAI:IBS
Number of subjects: 72

Group type: COMPARATOR
Intervention: Paper questionnaire for EQ-5D
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ease of use comparison between EDC and paper
Number of subjects: 72
Study: 15599140

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (Xigris) 24 microg/kg/hr for 96 hrs
Number of subjects: 1690
Study: 11257651

Group type: EXPERIMENTAL
Intervention: ALA fluorescence endoscopy
Number of subjects: 102

Group type: COMPARATOR
Intervention: White light endoscopy
Number of subjects: 102
Study: 9454481

Group type: EXPERIMENTAL
Intervention: Dacron prostheses
Number of subjects: 40

Group type: COMPARATOR
Intervention: PTFE prostheses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8217359

Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control
Number of subjects: 177
Study: 3304522

Group type: EXPERIMENTAL
Intervention: Urethral catheterization
Number of subjects: 66

Group type: COMPARATOR
Intervention: Suprapubic catheterization
Number of subjects: 66
Study: 24933484

Group type: EXPERIMENTAL
Intervention: Approach/right-hand contractions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Withdrawal/left-hand contractions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control/no contraction
Number of subjects: 75
Study: 24102666

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 88
Study: 21318452

Group type: EXPERIMENTAL
Intervention: Low-dose omega 3 fatty acids (1 gram of fish oil capsule containing 300 mg of eicosapentaenoic acid and docosahexaenoic acid daily for 6 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 19752672

Group type: EXPERIMENTAL
Intervention: SHARP program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 17766533

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 11292954

Group type: EXPERIMENTAL
Intervention: MPFF (2 tablets daily for 24 weeks)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (standard compressive therapy plus external treatment)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MPFF (for ulcers <3 cm)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (for ulcers <3 cm)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MPFF (for ulcers between 3 and 6 cm)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (for ulcers between 3 and 6 cm)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: MPFF
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control
Number of subjects: 140
Study: 9801287

Group type: EXPERIMENTAL
Intervention: Isopropanol 70%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isopropanol 80%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isopropanol 90%
Number of subjects: 20

Group type: COMPARATOR
Intervention: n-Propanol 60% (control)
Number of subjects: 20
Study: 8033573

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 22

Group type: COMPARATOR
Intervention: No acyclovir (Control)
Number of subjects: 22
Study: 2575375

Group type: EXPERIMENTAL
Intervention: Breathing Retraining with Cognitive Restructuring (BRCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded self‐exposure in vivo (EXP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of BRCR and EXP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments (BRCR, EXP, Combination)
Number of subjects: 0
Study: 1097600

Group type: EXPERIMENTAL
Intervention: Levoamphetamine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 22
Study: 31126345

Group type: EXPERIMENTAL
Intervention: Families Improving Together (FIT) for Weight Loss intervention
Number of subjects: 82
Study: 23246443

Group type: EXPERIMENTAL
Intervention: Teacher-led structured PA session
Number of subjects: 200

Group type: COMPARATOR
Intervention: No structured PA session
Number of subjects: 200
Study: 21716975

Group type: EXPERIMENTAL
Intervention: Prefabricated glass fiber posts
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Custom‐made glass fiber posts
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Composite cores without posts
Number of subjects: 144

Group type: COMPARATOR
Intervention: Gold alloy‐based posts and cores
Number of subjects: 144
Study: 18295060

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 0
Study: 16483549

Group type: EXPERIMENTAL
Intervention: Naltrexone and/or acamprosate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 12879276

Group type: EXPERIMENTAL
Intervention: Single 5-ml intramuscular injection of 250 mg fulvestrant
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Two 2.5-ml intramuscular injections with a total of 250 mg fulvestrant
Number of subjects: 100
Study: 10651750

Group type: EXPERIMENTAL
Intervention: Untreated acromegalic patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Treated acromegalic patients (with slow-release octreotide)
Number of subjects: 19

Group type: COMPARATOR
Intervention: GH-deficient patients (without GH replacement)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GH-deficient patients (during GH replacement)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acromegalic patients and GH-deficient patients (both treated and untreated)
Number of subjects: 19
Study: 9350368

Group type: EXPERIMENTAL
Intervention: Tracheal extubation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LMA removal
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison of extubation vs LMA removal
Number of subjects: 80
Study: 1610026

Group type: EXPERIMENTAL
Intervention: Slo-bid 800 mg once-a-day in the morning for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slo-bid 800 mg once-a-day in the evening for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theo-24
Number of subjects: 12
Study: 4037866

Group type: EXPERIMENTAL
Intervention: Lactation nurse assistance during early weeks after parturition (both in hospital and at home)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no lactation nurse assistance)
Number of subjects: 0
Study: 30904402

Group type: EXPERIMENTAL
Intervention: Low-threat message condition
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Moderate threat message condition
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: High-threat message condition
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 117
Study: 27870481

Group type: EXPERIMENTAL
Intervention: PF-04937319 (split-dose, 150+100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-04937319 (once daily, 300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg once daily)
Number of subjects: 0
Study: 24318457

Group type: EXPERIMENTAL
Intervention: Bowel ligatures placed 3, 5, 10 cm from the tumor proximally and distally before dissection
Number of subjects: 20

Group type: COMPARATOR
Intervention: No ligatures placed until immediately before specimen removal
Number of subjects: 20
Study: 23488264

Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0
Study: 20878044

Group type: EXPERIMENTAL
Intervention: Twice/week training (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Once/week training (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Once/2 weeks training (group 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 40
Study: 18061012

Group type: EXPERIMENTAL
Intervention: Clinical Information Systems (CIS) implementation
Number of subjects: 0
Study: 15284729

Group type: COMPARATOR
Intervention: Normal pregnancy (n=61)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Early-onset preeclampsia (<=34 weeks)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Severe preeclampsia
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 122
Study: 11338723

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream, 0.05%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Hydrocortisone-17-butyrate cream, 0.1%
Number of subjects: 125
Study: 9251612

Group type: EXPERIMENTAL
Intervention: rhG-CSF (75 micrograms/day, subcutaneously)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no rhG-CSF)
Number of subjects: 29
Study: 7948154

Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 25% podophyllin resin
Number of subjects: 0
Study: 3215869

Group type: COMPARATOR
Intervention: Ambient CO at 0 ppm
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ambient CO at 50 ppm
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ambient CO at 100 ppm
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ambient CO at 150 ppm
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Altitude at 55 m
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Altitude at 3,048 m
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Maximal work loads
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Altitude and CO hypoxias
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Increasing altitude
Number of subjects: 23
Study: 29878044

Group type: EXPERIMENTAL
Intervention: Maternal FADS1 variant rs174546
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Offspring and maternal FADS3 variants
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: rs174450 minor allele homozygotes
Number of subjects: 898
Study: 27212198

Group type: EXPERIMENTAL
Intervention: Cetuximab-induced skin rash (grade 2 to 4)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Cetuximab-induced skin rash (grade 2 to 4) in p16-negative patients
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Acute in-field radiation dermatitis (grade 2 to 4)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Cetuximab-induced skin rash (grade 0 to 1)
Number of subjects: 602
Study: 26251182

Group type: EXPERIMENTAL
Intervention: Acute Heart Failure (AHF)
Number of subjects: 10730

Group type: EXPERIMENTAL
Intervention: Sub‐Acute Heart Failure (sub‐AHF)
Number of subjects: 10730

Group type: EXPERIMENTAL
Intervention: Chronic Heart Failure (Cr‐HF)
Number of subjects: 10730
Study: 22685164

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) - 18-24 g protein and 500 kcal per day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Hospital diet only (Control)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS)
Number of subjects: 126
Study: 21913864

Group type: COMPARATOR
Intervention: 3 × 15 minutes (n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 × 45 minutes (n=15)
Number of subjects: 30
Study: 18254433

Group type: EXPERIMENTAL
Intervention: Mentoring group (tutoring conversational skills to ESL students for 1 hour twice per week for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mentoring group
Number of subjects: 0
Study: 16303153

Group type: COMPARATOR
Intervention: Control group (8 hours of sleep)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sleep Deprived group (2 hours of sleep)
Number of subjects: 17
Study: 12684745

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) with immune-enhancing formula
Number of subjects: 39

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN)
Number of subjects: 39
Study: 10856142

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study: 9663841

Group type: EXPERIMENTAL
Intervention: Dual or triple combination therapies including one proton pump inhibitor (30 mg/day lansoprazole or 20 mg/day omeprazole) and one or two antibiotics (500 mg AMOX, 200 mg CLAR or 250 mg MNZ twice a day)
Number of subjects: 290
Study: 1347332

Group type: EXPERIMENTAL
Intervention: Lansoprazole (158 patients, gastric ulcer, treated for 8 weeks)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Famotidine (158 patients, gastric ulcer, treated for 8 weeks)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Lansoprazole (148 patients, duodenal ulcer, treated for 6 weeks)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Famotidine (143 patients, duodenal ulcer, treated for 6 weeks)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Lansoprazole (gastric ulcer)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Famotidine (gastric ulcer)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Lansoprazole (duodenal ulcer)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Famotidine (duodenal ulcer)
Number of subjects: 607
Study: 2579716

Group type: EXPERIMENTAL
Intervention: 270 cGy x 15 fractions
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 300 cGy x 10 fractions
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 300 cGy x 5 fractions
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 400 cGy x 5 fractions
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 500 cGy x 5 fractions
Number of subjects: 759
Study: 30855089

Group type: EXPERIMENTAL
Intervention: Large-field irradiation (LFI; tumor bed and elective lymph node region)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Small-field irradiation (SFI; tumor bed only)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Large-field irradiation (LFI)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Small-field irradiation (SFI)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both LFI and SFI
Number of subjects: 121
Study: 28506664

Group type: EXPERIMENTAL
Intervention: Heliox (70:30) via high flow nasal cannula at 8 L/min for 24 hours
Number of subjects: 48

Group type: COMPARATOR
Intervention: Air–oxygen mixture 30% via high flow nasal cannula at 8 L/min for 24 hours
Number of subjects: 48
Study: 26917493

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coronally advanced flap with porcine collagen matrix (CAF + CM)
Number of subjects: 40
Study: 24885289

Group type: EXPERIMENTAL
Intervention: Intensive, response-based reading intervention over 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Business-as-usual condition
Number of subjects: 0
Study: 22278891

Group type: EXPERIMENTAL
Intervention: Portable bladder scanner
Number of subjects: 145

Group type: COMPARATOR
Intervention: Traditional method (Control)
Number of subjects: 145
Study: 20424499

Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI) in diabetic patients
Number of subjects: 361

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 361
Study: 18576906

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day in HIV-infected patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day in HIV-negative patients (control)
Number of subjects: 32
Study: 15860471

Group type: EXPERIMENTAL
Intervention: RCT/VES
Number of subjects: 84

Group type: COMPARATOR
Intervention: RCT/C
Number of subjects: 84
Study: 12424548

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 10068105

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Matched controls without shunts
Number of subjects: 165
Study: 1709566

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Inert placebo tablet
Number of subjects: 54

Group type: COMPARATOR
Intervention: No hypnotic
Number of subjects: 54
Study: 6130752

Group type: EXPERIMENTAL
Intervention: Imipramine (up to 200 mg/day for 28 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure (3 hours total)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Therapist-aided relaxation (3 hours total)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Self-exposure homework
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31764732

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 61

Group type: COMPARATOR
Intervention: Acetaminophen (Control)
Number of subjects: 61
Study: 30032288

Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 106
Study: 27027629

Group type: EXPERIMENTAL
Intervention: Pulsed irradiation (1 second on, 1 second off) for 8 minutes
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous irradiation for 4 minutes
Number of subjects: 70
Study: 25285540

Group type: EXPERIMENTAL
Intervention: In-hospital, one-on-one, self-management education by a dedicated language-concordant registered nurse combined with telephone follow-up after discharge from a nurse practitioner.
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study: 22287172

Group type: EXPERIMENTAL
Intervention: OsPr‐CMC (OPTIVE®)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Na‐HY (VISMED®)
Number of subjects: 82
Study: 20114099

Group type: EXPERIMENTAL
Intervention: Unilateral hamstring muscle stretching
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bilateral hamstring muscle stretching
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 17084887

Group type: EXPERIMENTAL
Intervention: Basic curriculum intervention
Number of subjects: 7079

Group type: EXPERIMENTAL
Intervention: Basic with peer involvement intervention
Number of subjects: 7079

Group type: EXPERIMENTAL
Intervention: Basic with parent involvement intervention
Number of subjects: 7079

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7079
Study: 16892644

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no laser photocoagulation)
Number of subjects: 29
Study: 15280979

Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 117
Study: 10735499

Group type: COMPARATOR
Intervention: Dacarbazine and interferon-alpha (DTIC/IFN)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dacarbazine, BCNU, cisplatin and tamoxifen (DBCT)
Number of subjects: 100
Study: 8679310

Group type: EXPERIMENTAL
Intervention: Olfactory stimulation in HIV-infected patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Olfactory stimulation in control subjects
Number of subjects: 10
Study: 1558501

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine hydrochloride
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiologic saline
Number of subjects: 50